As the Senate Finance Committee questions some of our pharmaceutical industry leadership, there are obviously strong opinions and emotions around this topic. Here’s the net message that should be given and heard: rebates definitely affect how products are priced. Even before talking about PBMs, a manufacturer will consider statutory rebates such as what is due […]Read Full Article
Welcome to the Blue Fin Group Information Library. Our consultants regularly publish white papers, case studies and articles, lead workshops, deliver speaking engagements, and share opinions on topics of interest to decision makers in the healthcare industry.
You don’t become an industry leader without having alot to say—click on the video vignettes below to hear our expert’s perspectives on a range of topics.
Blue Fin Group is often sought out as an expert commentator by industry publications — featuring our latest thinking and timely insights on the issues that matter most to the healthcare industry.
Blue Fin Group keeps a lens trained on many facets of the healthcare industry, and our white papers focus on singular topics that are relevant and timely. Known for our out-of-the-box thinking, these insights provide a deeper dive or different viewpoint from what others in the industry provide.
Case studies that show the transformation from challenge to solution. Each one details the existing situation, Blue Fin Group’s unique approach, the solution deployed, and the results achieved on behalf of the client. At Blue Fin Group, we deliver Deep Knowledge. Powerful Results.
Deep knowledge, unique insights and powerful perspectives focused on the healthcare industry, provided by Blue Fin Group associates.
Pharmaceutical manufacturers and Integrated Delivery Networks (IDNs) are descending upon Philadelphia this week to discuss how we’ve moved the ball down the field in terms of the IDN model evolution and manufacturer engagement. I’m reinvigorated to take on this challenge of helping to unite our fragmented healthcare ecosystem. This conference has been a great platform […]Read Full Article
In this series of blog posts, we will visit the implications of co-pay accumulators across the 5 Ps—patients, prescribers, products, pharmacies, and payers—and discuss in more detail the Chutes and Ladders reality that it causes.Read Full Article
Rising costs and less than ideal patient outcomes demand the attention of public and private healthcare stakeholders and magnify the need to shift toward value-based healthcare models.Read Full Article
Principal Consultant Sean Duffy outlines a series of questions he hopes to find perspectives on at the upcoming CBI Specialty Pharmacy Network Design conference.Read Full Article
ASCO’s 2018 theme, “Delivering Discoveries: Expanding the Reach of Precision Medicine,” certainly played out this year from the plenary podium to abstracts to posters and the exhibit hall. Each of the Blue Fin Group team who attended exceeded our daily fitness steps in the search for knowledge, both to bring to our colleagues, and to […]Read Full Article
Jan Nielsen, Senior Principal, shares thoughts on PROs – Patient Reported Outcomes — as a wonderful opportunity to improve the patient journey, communication between patient and physician, and the overall patient experience.Read Full Article
It’s that time of the year again – ASCO (American Society of Clinical Oncology) – where the bright and caring minds of the world’s cancer experts convene for the newest advances in cancer care. No other conference or summit is quite like ASCO and the anticipation of life changing treatments for patients and their caregivers. […]Read Full Article